Oxford-BMS Fellowship

Principle Investigators should apply for fellowship funding to support clinical (Grade E64) or basic research scientists (Grade 7/8) committed to translational science and interested in obtaining experience with drug development in an industrial setting. 

Fellowship applications may include a named fellow, but this is not mandatory. It is expected that a suitable fellowship candidate will be identified by the Principle Investigator within 6 months of notification of successful project selection.

The proposed fellowship needs to align with BMS’s fields of interest as listed below.

1. Novel targets, biomarkers, cellular therapeutic approaches, or translational models in one of the following areas:

• immuno-oncology;
• neurodegenerative and neuroinflammatory diseases including Alzheimer’s, Parkinson’s, ALS, FTD and MS;
• fibrosing disorders including IPF, NASH, scleroderma, and Renal Fibrosis;
• rheumatic and dermatologic disorders including RA, SLE, spondyloarthropathies, psoriasis and atopic dermatitis; 
• haematologic disorders including AML, Myeloma, DLBCL;
• chronic heart failure (either with preserved or reduced ejection fraction).

2. Methods for evaluating biochemical, cellular, tissue and phenotypic consequences of
modulating epigenetic targets.

3. Methods for immuno-phenotyping of human subjects in oncology and autoimmunity

4. Novel imaging approaches to measuring disease activity in the above areas.

This scheme is currently closed for new applications 

Stage 1 - Pre-application questions and meeting with BMS

Stage 1  

The Oxford-BMS Fellowship Programme strongly encourages you to take pre-application steps before submitting your application in IRAMS. The pre-application steps ensure that your proposal is in line with BMS’s areas of research interest and involves some pre-application questions and a meeting with BMS.

Stage 2 - Full application

Full applications should be made through IRAMS. The full application form should be uploaded to the system and page limitations specified in the form need to be respected (see section 6 of the guidance for applicants for more detail). Please be aware that only one single PDF can be uploaded to IRAMS - multiple PDFs will need to be combined. Furthermore, a basic budget breakdown needs to be filled in the online application form.  

Prospective Principle Investigator applicants should read this application guidance

The 2020 call for Fellowship Proposals has now closed. 

Please do check back early 2021 for information on future opportunities. 

For all enquiries please contact Charlotte Bell, Industry Partnerships Manager, Medical Sciences Industry Partnerships Office

Email: charlotte.bell@medsci.ox.ac.uk

Telephone: 01865 289877

JOINT STEERING COMMITTEE

Professor Sir Marc Feldmann (Oxford)

Professor Fiona Powrie (Oxford)

Professor Irene Tracey (Oxford)

Professor Chas Bountra (Oxford)

Dr. Maxine Allen (Oxford)

Dr. Rupert Vessey (BMS)

Dr. Leon Carayannopoulos (BMS)

Dr. James Carmichael (BMS)

Dr. Anjan Thakurta (BMS)

 Current Fellows

Nora Bengoa-Vergniory	Liam Brown	Pablo Cespedes
'Inhibition of alpha-synuclein aggregation and glial activation as a therapeutic strategy for Parkinson’s disease'	'A computational framework for T cell trafficking and dynamics in anti-tumour immune responses'	'Studying the effects of citrullination on the dynamics of receptor-ligand pair interactions at the Immune Synapse'
PI: Richard Wade-Martins	PI: Mark Coles, Eamonn Gaffney
Hebe Chen	Liliana Cifuentes	Amy Cross
'Investigation of epigenetic and post-translational modifications in altered STAT3'	'Protein kinase C-θ and PD-1 as a therapeutic target in inflammatory arthritis'	'Combination therapy of low dose regulatory T cells and low dose IL-2 to prevent rejection in transplantation'
PI: Professor Holm Uhlig & Dr. Arian Laurence	PI: Graham Ogg, Peter Taylor, Mike Dustin	PI: Dr Joanna Hester & Dr Fadi Issa
Melanie Dunstan	Michael Fitzpatrick	Stefania Giussani
'Ultra low-dose IL-2 therapy in autoimmune diabetes'	'Use of unbiased T-cell receptor repertoire sequencing to identify novel T-cell subsets involved in coeliac disease and increase the accuracy of the diagnosis of gluten sensitivity'	'Investigation of T cell reactivity to alpha-synuclein in Parkinson's disease'
PI: John Todd, Claudia Monaco	PI: Elizabeth Soilleux, Paul Klennerman
Sarah Gooding	Tariq Khoyratty	Sarah Sasson
'Determining changes in clonal/sub clonal architecture and relation to immune marrow environment enabling tumour persistence/relapse in myeloma'	'Defining an early signature of neutrophil extracellular trap formative predictive of responses to PAD4/2 inhibitors in rheumatic patients'	'Checkpoint blockade-mediated autoimmune colitis as a model for gut immune homeostasis'
PI: Paresh Vyas, Udo Oppermann, Karthik Ramasamy	PI: Irina Udalova, Raashid Luqman	PI: Paul Klenerman, Oliver Brain

Past Fellows

Hannah Chen	Thomas Layton	Heidi Olzscha
'Definition of new drug targets for fibrosis in Crohns'	'Single cell analysis of the fibrotic landscape in Dupuytren's Disease'	'Unravelling the role of E2F-1 citrullination in inflammatory disease'
PI: Alison Simmons	PI: Jagdeep Nanchahal	PI: Nick La Thangue
Lynn Quek
'Clonal and Functional heterogeneity in AG221-treated IDH2 mutant Acute Myeloid Leukaemia'
PI: Paresh Vyas